Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.

J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug

Johnson & Johnson JNJ, -0.61% said Friday it is committing $500 million over four years to help end the epidemics of HIV and Tuberculosis.

Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics

J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.

J&J Settles Ahead of Multi-District Opioid Trial, Stock Up

Shares of Johnson & Johnson have fallen mostly flat due to the ongoing opioid lawsuits. Here are three reasons JNJ stock should rebound.

3 Things Investors Should Know About the Opioid Lawsuits Against Johnson & Johnson

Johnson and Johnson stock has been a loser for sometime. But this is presenting an opportunity for investors.

3 Reasons Why Johnson and Johnson Stock Will Get Back on Track

Johnson & Johnson (NYSE: JNJ) announced a $20.4-million agreement Wednesday with the Ohio counties of Cuyahoga and Summit to settle an opioid lawsuit with the state, removing the company from federal multidistrict litigation.

Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement

Johnson & Johnson (NYSE: JNJ) surprised investors on Wednesday morning by announcing a $10 million settlement with two Ohio counties ahead of an upcoming opioid trial.

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

Johnson & Johnson's stock JNJ, +2.23% rallied 2.3% in morning trading Wednesday, and was the only gainer among the Dow Jones Industrial Average's DJIA, -1.15% 30 components, after drug maker announced a settlement with two Ohio counties ahead of an upcoming opioid trial.

Johnson & Johnson's stock the lone Dow gainer after opioid-related settlement with Ohio counties

Johnson & Johnson  said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation's opioid epidemic.

Johnson & Johnson settles Ohio lawsuits to avoid federal trial

Johnson & Johnson  said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties in a lawsuit that accused the drugmaker of contributing to an U.S. opioid addiction epidemic.

J&J to pay $20.4 million to settle opioid lawsuits with two Ohio counties

Late Tuesday, Johnson & Johnson settled claims out of Ohio that the pharmaceutical company's misleading marketing led to two counties' opioid crisis. J&J stock rose a fraction after hours.

Pharma Giant J&J Avoids Opioid Trial In Ohio With $10 Million Settlement

Johnson & Johnson said on Tuesday it settled with two Ohio counties, ahead of an opioid trial scheduled to begin on Oct. 21.

Johnson & Johnson settles with Ohio counties ahead of opioid trial

Contrarian investors can pounce on attractive prices today in JNJ stock shares.
The post Negative Press Presents a Buying Opportunity with JNJ Stock appeared first on InvestorPlace.

Negative Press Presents a Buying Opportunity with JNJ Stock

Johnson & Johnson stock has been hit by legal worries over the past year. But once those worries are resolved, JNJ should rally again.

Johnson & Johnson Can Overcome Its Legal Issues

JNJ has a moderate long-term outlook that is strengthened by its robust business segments and strong management team.

Dividend King: Johnson & Johnson Poised For Another Dividend Boost

Johnson and Johnson offers opportunity, but there's near-term headline risk. Here's what JNJ stock investors should expect.

Can Johnson and Johnson Stock Overcome Opiod Implications?

Enterprise Products Partners

Imperial Brands PLC

Altria

UnitedHealth Group

The 24-hour news cycle means we're constantly inundated with scary headlines creating fear of an imminent market downturn.

The Best Dividend Stocks To Buy In October

Caterpillar

Pfizer

Walgreens

With just over one quarter left in 2019, it has been another banner year for stock market investors, with double-digit gains in all three major averages.

5 Dow Jones Industrial Average 2019 Laggards Could Be Big Q4 Winners

As we start another earnings season, I do not yet feel comfortable going long Johnson and Johnson stock.
The post Should You Buy Johnson & Johnson Stock in October?

Should You Buy Johnson & Johnson Stock in October?

Johnson and Johnson has a rather healthy drug menu with some heavy-hitters about to be added to it. But investors haven't bothered to notice.

Don’t Ignore the Johnson and Johnson Pharmaceutical Pipeline

Johnson & Johnson (JNJ) closed the most recent trading day at $131.55, moving -0.14% from the previous trading session.

Johnson & Johnson (JNJ) Stock Moves -0.14%: What You Should Know

Cardinal Health

CVS Health

Mallinckrodt PLC

Teva Pharmaceutical

The health care industry could be forced to pay out as much as $150 billion.

5 Stocks That Could Get Crushed By Opioid Lawsuit Tidal Wave

Dow stock Johnson & Johnson could outperform on the charts next month

Johnson & Johnson Stock Flashing Post-Fed Signal

For completely understandable reasons, the markets have a dim view on Johnson and Johnson stock. That said, this isn’t the first time that a company has faced serious scandals and lived to tell the tale.

Why Contrarians May Want to Take a Look at JNJ Stock

Allergan

Sientra

As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

News for Johnson & Johnson Stock (JNJ)